NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Consensus Rating of “Moderate Buy” by Brokerages

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has been given an average rating of “Moderate Buy” by the six ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $36.50.

A number of equities analysts recently commented on NRXP shares. HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, October 16th. Ascendiant Capital Markets lifted their price target on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. D. Boral Capital reaffirmed a “buy” rating and set a $34.00 price objective on shares of NRx Pharmaceuticals in a research report on Tuesday, December 2nd. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, October 8th.

Hedge Funds Weigh In On NRx Pharmaceuticals

Several large investors have recently bought and sold shares of NRXP. Anson Funds Management LP grew its holdings in shares of NRx Pharmaceuticals by 535.1% during the first quarter. Anson Funds Management LP now owns 1,179,061 shares of the company’s stock worth $2,417,000 after purchasing an additional 993,401 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares during the period. Geode Capital Management LLC grew its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the last quarter. Two Sigma Investments LP increased its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the period. Finally, AdvisorShares Investments LLC increased its position in NRx Pharmaceuticals by 29.7% during the third quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Stock Down 3.3%

Shares of NASDAQ:NRXP opened at $2.36 on Monday. NRx Pharmaceuticals has a fifty-two week low of $1.15 and a fifty-two week high of $6.01. The firm’s 50 day moving average price is $2.82 and its 200 day moving average price is $2.89. The stock has a market cap of $66.32 million, a price-to-earnings ratio of -1.00 and a beta of 1.91.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The business had revenue of $0.24 million for the quarter, compared to the consensus estimate of $6.83 million. On average, equities analysts anticipate that NRx Pharmaceuticals will post -1.75 EPS for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.